Saccharomyces cerevisiae var. boulardii as a eukaryotic probiotic and its therapeutic functions

Document Type: Review Article

Authors

1 Department of Food Hygiene, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

2 Mycology Research Center, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

Abstract

Fuller, in 1989, described probiotic microorganisms as “a live microbial feed supplement,
which beneficially affects the host animal, by improving its intestinal microbial balance”.
Saccharomyces cerevisiae var. boulardii (S.boulardii) is an accurate probiotic yeast idol.
The detection and budding of S.boulardiiis firmly related to the impression of healthiness
to promote microorganisms from foodstuff. S.boulardiiis similar to S.cerevisiae in that it
equally does not have the capability to penetrate into tissues like the Candida species is
able to, hence they are not invasive. Some printed medicinal researches have shown the
effectiveness and safety of S.boulardii for different illness indications in both adults and
children. On the subject of the therapy employed, diverse indications of S.boulardii are as
follows: Anticipation of antibiotic related diarrhea, recurring Clostridium difficile related
diarrhea and colitis, severe viral and bacterial diarrhea, travelers’ diarrhea, antiinflammatory
bowel syndromes as well as Crohn's disease and so on. These days,
S.boulardii is regularly marketed as a probiotic in a lyophilized shape and is often
referred to as S.boulardii lyo.

Keywords


1. Barc, M.C., Charrin-Sarnel, C., Rochet, V., Bourlioux, F., Sandre, C., Boureau, H., Dore, J., Collignon, A., 2008. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe, 14: 229-233.
2. Baumgart, D., 2007. The probiotic yeast Saccharomyces boulardii inhibits DC-induced activationof naïve T-cells. Gastroenterology, 135(4):A-559.
3. Beaugerie, L., Petit, J.C., 2004.Antibiotic-associated diarrhea. Best Practice and Research Clinical Gastroenterology, 18: 337-352.
4. Bisson, J.F., Hidalgo, S., Rozan, P., Messaoudi, M., 2010. Preventive effects of different probiotic formulations on travelers’ diarrhea model in Wistar rats: preventive effects of probiotics on TD. Digestive Diseases and Sciences, 55:911-919.
5. Buts, J.P., 2009. Twenty-five years of research on Saccharomyces boulardii trophic effects:updates and perspectives. Digestive Diseases and Sciences, 54(1):15-8.
6. Buts, J.P., Bernasconi, P., Vaerman, J.P., Dive, C., 1990. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences, 35(2):251-256.
7. Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., De Meyer, R., 1986. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20(2):192-196.
8. Buts, J.P., De Keyser, N., 2006. Effects of Saccharomyces boulardii on Intestinal Mucosa. Digestive Diseases and Sciences. 51(8):1485-1492.
9. Buts, J.P., De Keyser, N., 2010. Interaction of Saccharomyces boulardii with intestinal brush bordermembranes: key to probiotic 

1. Barc, M.C., Charrin-Sarnel, C., Rochet, V., Bourlioux, F., Sandre, C., Boureau, H., Dore, J., Collignon, A., 2008. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii. Anaerobe, 14: 229-233.
2. Baumgart, D., 2007. The probiotic yeast Saccharomyces boulardii inhibits DC-induced activationof naïve T-cells. Gastroenterology, 135(4):A-559.
3. Beaugerie, L., Petit, J.C., 2004.Antibiotic-associated diarrhea. Best Practice and Research Clinical Gastroenterology, 18: 337-352.
4. Bisson, J.F., Hidalgo, S., Rozan, P., Messaoudi, M., 2010. Preventive effects of different probiotic formulations on travelers’ diarrhea model in Wistar rats: preventive effects of probiotics on TD. Digestive Diseases and Sciences, 55:911-919.
5. Buts, J.P., 2009. Twenty-five years of research on Saccharomyces boulardii trophic effects:updates and perspectives. Digestive Diseases and Sciences, 54(1):15-8.
6. Buts, J.P., Bernasconi, P., Vaerman, J.P., Dive, C., 1990. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Digestive Diseases and Sciences, 35(2):251-256.
7. Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., De Meyer, R., 1986. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20(2):192-196.
8. Buts, J.P., De Keyser, N., 2006. Effects of Saccharomyces boulardii on Intestinal Mucosa. Digestive Diseases and Sciences. 51(8):1485-1492.
9. Buts, J.P., De Keyser, N., 2010. Interaction of Saccharomyces boulardii with intestinal brush bordermembranes: key to probiotic 

26. Diezmann, S., Dietrich, F.S., 2009. Saccharomyces cerevisiae: Population divergence and resistanceto oxidative stress in clinical, domesticated and wild isolates. PloSOne. 4(4):e5317.
27. Dinleyici, E.C., Eren, M., Dogan, N., Reyhanioglu, S., Yargic, Z.A., Vandenplas, Y., 2011. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. Parasitology Research, 108:541-545.
28. Dinleyici, E.C., Eren, M., Yargic, Z.A., Dogan, N., Vandenplas, Y., 2009. Clinical efficacy of Saccharomyces boulardii and metronidazole comparedwith metronidazole alone in children with acute bloody diarrhea caused by amebiasis: a prospective, randomized, open label study. The American Journal of Tropical Medicine and Hygiene, 80:953-955.
29. Edwards-Ingram, L., Gent, M., Hoyle, D., Hayes, A., Stateva, L., Oliver, S.G., 2004. Comparativegenomic hybridization provides new insights into the molecular taxonomy of the Saccharomyces sensu stricto complex. Genome Research, 14(6):1043-1051.
30. Edwards-Ingram, L., Gitsham, P., Burton, N., Warhurst, G., Clarke, I., Hoyle, D., Oliver, S.G., and Stateva1, L., 2007. Genotypic and physiological characterization of Saccharomyces boulardii, the probioticstrain of Saccharomyces cerevisiae. Applied and Environmental Microbiology, 73(8):2458-2467.
31. Ferreira, I., Pinho, O., Vieira, E., Tavarela, J.G., 2010. Brewer's Saccharomyces yeast biomass: characteristics and potential applications. Trends in Food Science & Technology, 21(2):77-84.
32. Fidan, I., Kalkanci, A., Yesilyurt, E., Yalcin, B., Erdal, B., Kustimur, S. Imir, T., 2009. Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses, 52:29-34.
33. Floch, M.H., 2014. Recommendations for
probiotic use in humans-a 2014 update. Pharmaceuticals, 7(10): 999-1007.
34. Fuller, R., 1989. Probiotics in man and animals. The Journal of applied bacteriology, 66(5):365-378.
35. Gareau, M.G., Sherman, P.M., Walker, W.A., 2010. Probiotics and the gut microbiota in intestinal health and disease. Nature Reviews Gastroenterology and Hepatology,7:503-514.
36. Gedek, B.R., 1999. Adherence of Escherichia coli serogroup O157 and the Salmonella typhimurium mutant DT104 to the surface of Saccharomyces boulardii. Mycoses, 42(4):261-264.
37. Generoso, S.V., Viana, M.L., Santos, R.G., Arantes, R.M., Martins, F.S., Nicoli, J.R., Machado, J.A.N., Correia, M.I.T.D., Cardoso, V.N., 2011. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. European Journal Nutrition, 50:261-269.
38. Guandalini, S., 2011. Commentary on ‘Probiotics for treating acute infectious diarrhoea’. Evidence-Based Child Health: A Cochrane Review Journal, 6(6):2024-2025.
39. Guslandi, M., 2010. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. Journal of Clinical Gastroenterology, 344:385.
40. Guslandi, M., Giollo, P., Testoni, P.A., 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology and Hepatology, 15(6):697-698.
41. Guslandi, M., Mezzi, G., Sorghi, M., Testoni, P.A., 2000. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences, 45(7):1462-1464.
42. Heitman, J., 2006. Saccharomyces cerevisiae: an emerging and model pathogenic fungus. ASM Press, US.
43. Hennequin, C., Thierry, A., Richard, G.F., Lecointre, G., Nguyen, H.V., Gaillardin, C., Dujon, B., 2001. Microsatellite typing as a 

new tool for identification of Saccharomyces cerevisiae strains. Journal of Clinical Microbiology, 39(2):551-559.
44. Im, E., Pothoulakis, C., 2010. Recent advances in Saccharomyces boulardii research.Gastroenterologie clinique et biologique, 34(1):S62-70.
45. Klis, F.M., Boorsma, A., DeGroot, P.W.J., 2006. Cellwallconstruction in Saccharomyces cerevisiae. Yeast, 23:185-202.
46. Kollaritsch, H., Kemsner, P., Wiedermann, G., Scheiner, O., 1989. Prevention of traveler's diarrhoea. Comparison of different non-antibiotic preparations. Travel Medicine International Society, 9-17.
47. Kotowska, M., Albrecht, P., Szajewska, H., 2005. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 21(5):583-590.
48. Krasowska, A., Kubik, A., Prescha, A., Lukaszewicz, M., 2007. Assimilation of omega 3 and omega 6 fatty acids and removing of cholesterol from environment by Saccharomycescerevisiae and Saccharomyces boulardii strains. Journal of Biotechnology, 131(2):S63-S64.
49. Krasowska, A., Lukaszewicz, M., Bartosiewicz, D., Sigler, K., 2010. Cell ATP level of Saccharomyces cerevisiae sensitively responds to culture growth and drug-inflicted variations inmembrane integrity and PDR pump activity. Biochemical and Biophysical ResearchCommunications. 395(1):51-55.
50. Krasowska, A., Murzyn, A., Dyjankiewicz, A., Lukaszewicz, M., Dziadkowiec, D., 2009. Theantagonistic effect of Saccharomycesboulardii on Candida albicans filamentation, adhesion and biofilm formation. FEMS yeast research, 9(8):1312-1321.
51. Kurugöl, Z., Koturoğlu, G., 2005. Effects of Saccharomyces boulardii in children with acute diarrhea. Acta Paediatrica, 94(1):44-47.
52. Lee, S.K., Kim, Y.W., Chi, S.G., Joo, Y.S., Kim, H.J., 2009. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Digestive Diseases and Sciences, 54:255-263.
53. Lessard, M., Dupuis, M., Gagnon, N., Nadeau, E., Matte, J.J., Goulet, J., Fairbrother, J.M., 2009. Administration of Pediococcus acidilactici or Saccharomyces cerevisiaeboulardii modulates deve lopment of porcine mucosal immunity and reduces intestinal bacterial translocation after Escherichia coli challenge. Journal of Animal Science, 87:922-934.
54. Lukaszewicz, M., 2012. Probiotics, Chapter 16: Saccharomyces boulardii var. boulardii probiotic yeast. INTECH Press, US.
55. MacKenzie, D.A., Defernez, M., Dunn, W.B., Brown, M., Fuller, L.J., de Herrera, S.R., Günther, A., James, S.A., Eagles, J., Philo, M., Goodacre, R., Roberts, I.N., 2008. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed byphylogenetics and metabolomics. Yeast, 25(7):501-512.
56. Malgoire, J.Y., Bertout, S., Renaud, F., Bastide, J.M., Mallié, M., 2005. Typing of Saccharomycescerevisiae clinical strains by using microsatellite sequence polymorphism. Journal ofClinical Microbiology, 43(3):1133-1137.
57. Martins, F.S., Dalmasso, G., Arantes, R.M.E., Doye, A., Lemichez, E., Lagadec, P., Imbert, V., Peyron, J.F., Rampal, P., Nicoli, J.R., Czeruka, D., 2010. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One, 5:e8925.
58. Martins, F.S., Elian, S.D., Vieira, A.T., Tiago, F.C., Martins, A.K., Silva, F.C., Souza, E.L., Sousa, L.P., Araujo, H.R., Pimenta, P.F., Bonjardim, C.A., Arantes, R.M., Teixeira, M.M., Nicoli, J.R., 2011. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with 

signal pathways involved in the activation of inflammation in a murine model of typhoid fever.International Journal of Medical Microbiology, 301: 359-364.
59. Martins, F.S., Nardi, R.M.D., Arantes, R.M.E., Rosa, C.A., Neves, M.J., Nicoli, J.R., 2005. Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. The Journal of General and Applied Microbiology,51:83-92.
60. Maupas, J., Champemont, P., Delforge, M., 1983. Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double blind, placebo controlled study. Medicine Chirurgie Digestives, 12(1):77-79.
61. McCusker, J.H., Clemons, K.V., Stevens, D.A., Davis, R.W., 1994. Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics, 136(4):1261-1269.
62. McFarland, L.V., 2006. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. The American Journal of Gastroenterology, 101:812-822.
63. McFarland, L.V., 2007. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Medicine and Infectious Disease, 5(2):97–105.
64. McFarland, L.V., 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adultpatients. World journal of gastroenterology, 16(18): 2202-2222.
65. McFarland, L., Bernasconi, P., 1993. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbial Ecology in Health and Disease, 6(4):157-71.
66. McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Elmer, G.W., Moyer, K.A., Melcher, S.A.,Bowen, K.E., Cox, J.L., 1995. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. The American Journal of Gastroenterology, 90(3): 439-448.
67. McFarland, L.V., Surawicz, C.M., Greenberg, R.N., Fekety, R., Elmer, G.W., Moyer, K.A., Melcher, S.A., Bowen, K.E., Cox, J.L., Noorani, Z., Harrington, G., Rubin, M., Greenwald, D., 1994. A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. Journal of the American Medical Association, 271(24): 1913-1918.
68. Mirzaei, H., Pourjafar, H., Homayouni, A., 2012. Effect of calcium alginate and resistant starch microencapsulation on the survival rate of Lactobacillus acidophilus La5 and sensory properties in Iranian white brined cheese.Food Chemistry, 132: 1966-1970.
69. Mirzaei, H., pourjafar, H., Homayouni, A., 2011. The Effect of microencapsulation with calcium alginate and resistant starch on the Lactobacillus acidophilus (LA5) survival rate in simulated gastrointestinal juice conditions. Journal of Veterinary Research, 66(4): 337-342.
70. Mitterdorfer, G., Mayer, H.K., Kneifel, W., Viernstein, H., 2002. Clustering of Saccharomyces boulardii strains within the species S.cerevisiae using molecular typing techniques.Journal of Applied Microbiology, 93(4):521-530.
71. Murzyn, A., Krasowska, A., Augustyniak, D., Majkowska-Skrobek, G., Lukaszewicz, M., Dziadkowiec, D., 2010. The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco2 and Intestin 407. FEMS microbiology letters, 310(1):17-23.
72. Murzyn, A., Krasowska, A., Stefanowicz, P., Dziadkowiec, D., Lukaszewicz, M., 2010. Capric acidsecreted by S.boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PloS One. 5(8):e12050.
73. Ng, S.C., Kamm, M.A., Stagg, A.J., Knight, S.C., 2010. Intestinal dendritic cells: Their role in bacterialrecognition, lymphocyte homing, and intestinal inflammation. Inflammatory Bowel Diseases. 16(10):1787-1807. 

74. Pontier-Bres, R., Prodon, F., Munro, P., Rampal, P., Lemichez, E., Peyron, J.F., Czerucka, D., 2012. Modification of SalmonellaTyphimurium Motility by the Probiotic Yeast StrainSaccharomyces boulardii. PloS One.7(3):e33796.
75. Pothoulakis, C., 2009. Review article: anti-inflammatory mechanisms of action ofSaccharomycesboulardii. Alimentary pharmacology and therapeutics. 30(8):826-833.
76. Pourjafar, H., Ghasemnezhad, R., 2010. Probiotics as a suitable replacement for common antibiotics against infectious disease.Journal of IRIAF Health Administration, 13:72-77.
77. Pourjafar, H., Ghasemnezhad, R., 2013. Role of probiotic bacteria in cancer prevention. Pejvad, 1(4):129-134.
78. Pourjafar, H., Mirzaei, H., Ghasemnezhad, R., Homayouni, A., 2011.Study of morphological and protective characteristics of beads obtained from microencapsulation of Lactobacillus acidophilus probiotic as a predominant and natural flora in human gut. Journal of Army University Medical Science, 9(4):233-240.
79. Pourjafar, H., Mirzaei, H., Homayouni, A., 2010. Study of the survival rate of free and microencapsulated lactobacillus acidophilus La5 in Iranian white cheese during manufacture and storage.Iranian Veterinary Journal, 7:50-59.
80. Rajkowska, K., Kunicka-Styczynska, A., 2009. Phenotypic and genotypic characterization ofprobiotic yeasts. Biotechnology and Biotechnological Equipment, 23(2): 662-665.
81. Rajkowska, K., Kunicka-Styczynska, A., Rygala, A., 2012. Probiotic Activity of Saccharomyces cerevisiae var. boulardii Against Human Pathogens. Food Technology and Biotechnology, 50: 230-236.
82. Santino, I., Alari, A., Bono, S., Teti, E., Marangi, M., Bernardini, A., Magrini, L., Di Somma, S., Teggi, A., 2014. Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of
Clostridium difficile colitis with a probioticum.International Journal of Immunopathology and Pharmacology, 27(1):143-6.
83. Shareck, J., Belhumeur, P., 2011. Modulation of Morphogenesis in Candida albicans by Various Small Molecules. Eukaryotic Cell, 10(8):1004-1012.
84. Skovgaard, N., 2007. New trends in emerging pathogens. International Journal of Food Microbiology, 120(3):217-224.
85. Soccol, R.S., de Souza Vandenberghe, L.P., Spier, M.R., Pedroni Medeiros, A.B., Yamaguishi, C.T., De Dea Lindner, J., Pandey, A., Thomaz-Soccol, V., 2010. The Potential of Probiotics: A Review. Food Technology and Biotechnology, 48:413-434.
86. Sougioultzis, S., Simeonidis, S., Bhaskar, K.R., Chen, X., Anton, P.M., Keates, S., Pothoulakis, C.,Kelly, C.P., 2006. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κBmediated IL-8 gene expression. Biochemical and Biophysical Research Communications, 343(1):69-76.
87. Surawicz, C.M., 2010. The microbiota and infectious diarrhea. Gastroenterologie clinique et biologique. 34(1):S29-36.
88. Szajewska, H., Horvath, A., Piwowarczyk, A., 2010. Meta-analysis: the effects of Saccharomycesboulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Alimentary pharmacology and therapeutics, 32(9):1069-1079.
89. Szajewska, H., Mrukowicz, J., 2005. Metaanalysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Alimentary Pharmacology and Therapeutics, 22:365-372.
90. Szajewska, H., Skorka, A., 2009. Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Alimentary Pharmacology and Therapeutics, 30:960-961. 

91. Tasteyre, A., Barc, M.C., Karjalainen, T., Bourlioux, P., Collignon, A., 2002. Inhibition of in vitro celladherence of Clostridium difficile by Saccharomyces boulardii. Microbial Pathogenesis, 32(5):219-225.
92. Thomas, S., Metzke, D., Schmitz, J., Dörffel, Y., Baumgart, D.C., 2011. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 301(6):G1083-G1092.
93. Thomas, S., Przesdzing, I., Metzke, D., Schmitz, J., Radbruch, A., Baumgart, D.C., 2009. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clinical and Experimental Immunology, 155(1):78-87.
94. Tiago, F.C., Martins, F.S., Souza, E.L., Pimenta, P.F., Araujo, H.R., Castro, I.M., Brandão, R.L., Nicoli, J.R., 2012. Adhesion onyeast cell surface as a trapping mechanism of pathogenic bacteria by Saccharomycesprobiotics. Journal of Medical Microbiology, 61(9):1194-1207.
95. Toma, M.M., Raipulis, J., Kalnina, I., Rutkis, R., 2005.Effect of Probiotic Yeast on Genotoxicity. Food Technology and Biotechnology, 43:301-305.
96. Vandenplas, Y., Brunser, O., Szajewska, H., 2009. Saccharomyces boulardii in childhood. European Journal of Pediatrics, 168(3):253-265.
97. Villarruel, G., Rubio, D.M., Lopez, F., Cintioni, J., Gurevech, R., Romero, G., Vandenplas, Y., 2007. Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatrica, 96:538-541.
98. Vohra, A., Satyanarayana, T., 2012. Probiotic yeasts microorganisms in sustainable agricultureand biotechnology. In: Satyanarayana, T., Johri, B.N., Prakash, A., editors. Springer Press, Netherlands.
99. Whiteway, M., Oberholzer, U., 2004. Candida morphogenesis and host–pathogen
interactions. Current Opinion in Microbiology, 7(4):350-357.
100. Zanello, G., Berri, M., Dupont, J., Sizaret, P.Y., D'Inca, R., Salmon, H., Meurens, F., 2011. Saccharomyces cerevisiae modulates immune gene expressions and inhibits ETEC-mediated ERK1/2 andp38 signaling pathways in intestinal epithelial cells. PloS One. 6(4):e18573.
101. Zanello, G., Meurens, F., Berri, M., Salmon, H., 2009. Saccharomyces boulardii effects on gastro intestinal diseases. Current Issues in Molecular Biology, 11:47-58.
102. Zaouche, A., Loukil, C., De Lagausie, P., Peuchmaur, M., Macry, J., Fitoussi, F., Bernasconi, P., Bingen, E., Cezard, J.P., 2000. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation, and intestinal adaptation after small-bowel resection in rats. Journal of Gastroenterology, 35(2):160-165.